By Jim Adox, Managing Partner

Today, we’re announcing that Venture Investors Health Fund is becoming Clarevia Ventures (pronounced Claire-VEE-ah).
This is more than a new name. It is a clearer articulation of where we’ve been heading for years.

Our firm started 40 years ago as a generalist investor focused on Madison, Wisconsin. Over time, we grew and that changed. We became increasingly concentrated in healthcare, and for years now, that has been the center of gravity for the firm. We’ve maintained our roots in the Midwest and our close relationships with institutions like the University of Wisconsin–Madison and the University of Michigan, while expanding our network and our impact far beyond the region.

The new name reflects that evolution. It puts a sharper point on who we are, what we do, and how we work with founders.
Just as importantly, this is not about suddenly becoming something new. We have been building toward this for a long time. Now we have a name that better reflects it.

Why now

The short answer is that healthcare innovation has changed.

There is a tremendous amount of technology in healthcare now. From imaging and diagnostics, to robotics, AI, and gene sequencing, the field has become far more technical. At the same time, the rigor and the requirements around regulation have also gone up. The FDA has gotten tougher. The bar has risen. That changes what founders need from investors at the earliest stages.

Promising science is not enough. Capital is not enough. Founders need experienced partners who understand the intersection of healthcare and technology, who can help them think through the right clinical and regulatory path, and who know how to guide a company through the hard decisions early, when clarity matters most.

That is a big part of why this rebrand is happening now. It reflects a sharper focus on the role we play: helping early-stage medtech and life sciences companies move from breakthrough science to real patient impact.

Why Clarevia

The name Clarevia gets at something we believe deeply. It comes from a root meaning to illuminate, to make clear. That resonated with us because so much of what we do is help founders bring clarity to a path that can be difficult to see at the beginning.

In healthcare, many of the most important companies do not struggle because the science is weak. They struggle because the path forward is complex. There are hard decisions around clinical strategy, regulatory and reimbursement planning, team building, and commercialization. Those decisions come early, and they compound over time.

That is where clarity matters. And that is what we want the name Clarevia to stand for: helping founders sharpen strategy, refine focus, and see the opportunities and next steps more clearly.

What that looks like in practice

For us, this has always been about showing up and doing the hard work alongside founders. Sometimes that means helping shape the company early, before the path is obvious. Sometimes it means helping recruit the right team sooner. Sometimes it means bringing the right people into the room because we know what good looks like, and because we have built the network and credibility to reach highly experienced operators, executives, and advisors.

You can see that in HistoSonics. We were engaged early and stayed committed for the long haul. Our involvement went beyond capital and included hands-on support through the company’s clinical journey, including international trial work. HistoSonics is a reminder that success in healthcare rarely happens overnight. It takes patience, rigor, and a willingness to stay with a company through both the hard moments and the breakthroughs.

You can also see it in EarliPoint, where we played a leading role in the company’s Series B as well as the recruitment of the current CEO to refine the commercial path. That kind of work goes beyond providing capital. It means helping founders clarify the next steps, build with intention, and put the right foundations in place early.
These examples show how we work. We do not want to be distant observers. We want to be useful partners. We show up.

Looking ahead

Clarevia Ventures remains grounded in the same values and the same long-term commitment that have shaped this firm for four decades. As we move into the future, we are committed to helping bring more scientific breakthroughs out of the lab and into the world to improve patients’ lives.

Read our press release here: After 40 Years, Venture Investors Rebrands as Clarevia Ventures, Marking a Sharper Identity for Its Next Chapter in Healthcare Investing